Infectomics and autoinfectomics: A tool to study infectious-induced autoimmunity

Lupus

Volumn 24, Issue 4-5, 2015, Pages 364-373

  Bogdanos, D P ^a,b   Smyk, D S ^a   Rigopoulou, E I ^b   Sakkas, L I ^b   Shoenfeld, Y ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF THESSALY   (Greece)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Autoimmune disease; Autoimmunity; Environment; Genome; Immunology; Infection; Microbiome

Indexed keywords

ANCA ASSOCIATED VASCULITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; FECES ANALYSIS; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOASSAY; INFECTION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RNA SEQUENCE; SALIVA ANALYSIS; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; URINALYSIS; ANIMAL; ENVIRONMENTAL EXPOSURE; IMMUNOLOGY; MICROFLORA;

AUTOANTIBODY;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; ENVIRONMENTAL EXPOSURE; HUMANS; INFECTION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICROBIOTA; SCLERODERMA, SYSTEMIC;

EID: 84925632033     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314559088     Document Type: Article

References (99)

1. Smyk D, Rigopoulou EI, Baum H, Burroughs AK, Vergani D, Bogdanos DP. Autoimmunity and environment: Am I at risk? Clin Rev Allergy Immunol 2011; 42: 199-212.
2. Burek CL, Talor MV. Environmental triggers of autoimmune thyroiditis. J Autoimmun 2009; 33: 183-189.
3. Chighizola C, Meroni PL. The role of environmental estrogens and autoimmunity. Autoimmun Rev 2012; 11: A493-A501.
4. Cutolo M, Pizzorni C, Sulli A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 2011; 11: 84-87.
5. Hajas A, Sandor J, Csathy L, et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 2011; 10: 317-324.
6. Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: The conflicting relationship between humans and their environment. Autoimmun Rev 2008; 8: 1-4.
7. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: Infections and autoimmune disease. Clin Microbiol Rev 2006; 19: 80-94.
8. Anaya JM. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev 2012; 11: 781-784.
9. Costenbader KH, Gay S, Alarcón-Riquelme ME, Iaccarino L, Doria A. Genes, epigenetic regulation and environmental factors: Which is the most relevant in developing autoimmune diseases? Autoimmun Rev 2012; 11: 604-609.
10. Takahashi K. Influence of bacteria on epigenetic gene control. Cell Mol Life Sci 2014; 71: 1045-1054.
11. Tammen SA, Friso S, Choi SW. Epigenetics: The link between nature and nurture. Mol Aspects Med 2012; 34: 753-764.
12. Zhang L, Hou D, Chen X, et al. Exogenous plant MIR168a specifically targets mammalian LDLRAP1: Evidence of crosskingdom regulation by microRNA. Cell Res 2011; 22: 107-126.
13. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996; 39: 732-735.
14. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: Results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62: 835-841.
15. Hsieh LF, Wei JC, Lee HY, Chuang CC, Jiang JS, Chang KC. Aerobic capacity and its correlates in patients with ankylosing spondylitis. Int J Rheum Dis. Epub ahead of print 23 April 2014.
16. Bogdanos DP, Smyk DS, Rigopoulou EI, et al. Twin studies in autoimmune disease: Genetics, gender and environment. J Autoimmun 2012; 38: J156-J169.
17. Smyk DS, Rigopoulou EI, Muratori L, Burroughs AK, Bogdanos DP. Smoking as a risk factor for autoimmune liver disease: What we can learn from primary biliary cirrhosis. Ann Hepatol 2012; 11: 7-14.
18. de Pablo P, Chapple IL, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol 2009; 5: 218-224.
19. Arkema EV, Karlson EW, Costenbader KH. A prospective study of periodontal disease and risk of rheumatoid arthritis. J Rheumatol 2010; 37: 1800-1804.
20. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-1213.
21. Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, Bell JI. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci USA 1989; 86: 10049-10053.
22. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-916.
23. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-2219.
24. Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: An update. Joint Bone Spine 2007; 74: 418-426.
25. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 380-386.
26. Arkema EV, Goldstein BL, Robinson W, et al. Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: A nested case-control study. Arthritis Res Ther 2013; 15: R159.
27. Snir O, Widhe M, von Spee C, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: Association with HLA-DRB1 alleles. Ann Rheum Dis 2009; 68: 736-743.
28. van Beers JJ, Willemze A, Jansen JJ, et al. ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res Ther 2013; 15: R140.
29. Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 2008; 27: 511-513.
30. Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord 2007; 8: 37.
31. Scally SW, Petersen J, Law SC, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013; 210: 2569-2582.
32. Cantaert T, Brouard S, Thurlings RM, et al. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibodypositive rheumatoid arthritis. Arthritis Rheum 2009; 60: 1944-1956.
33. Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65: 366-371.
34. Vassallo R, Luckey D, Behrens M, et al. Cellular and humoral immunity in arthritis are profoundly influenced by the interaction between cigarette smoke effects and host HLA-DR and DQ genes. Clin Immunol 2014; 152: 25-35.
35. Abdullah SN, Farmer EA, Spargo L, Logan R, Gully N. Porphyromonas gingivalis peptidylarginine deiminase substrate specificity. Anaerobe 2013; 23: 102-108.
36. Lundberg K, Kinloch A, Fisher BA, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008; 58: 3009-3019.
37. Mahdi H, Fisher BA, Källberg H, et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009; 41: 1319-1324.
38. Reichert S, Haffner M, Keyßer G, et al. Detection of oral bacterial DNA in synovial fluid. J Clin Periodontol 2013; 40: 591-598.
39. Sahingur SE, Xia XJ, Alamgir S, Honma K, Sharma A, Schenkein HA. DNA from Porphyromonas gingivalis and Tannerella forsythia induce cytokine production in human monocytic cell lines. Mol Oral Microbiol 2010; 25: 123-135.
40. Karlson EW, Chang SC, Cui J, et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis 2009; 69: 54-60.
41. van der Woude D, Alemayehu WG, Verduijn W, et al. Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat Genet 2010; 42: 814-816; author reply 816.
42. Willemze A, van der Woude D, Ghidey W, et al. The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis Rheum 2011; 63: 1823-1832.
43. Hill JA, Bell DA, Brintnell W, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008; 205: 967-979.
44. Sokolove J, Zhao X, Chandra PE, Robinson WH. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 2010; 63: 53-62.
45. Willis VC, Gizinski AM, Banda NK, et al. N-alpha-benzoyl-N5-(2- chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol 2011; 186: 4396-4404.
46. Maresz KJ, Hellvard A, Sroka A, et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog 2013; 9: e1003627.
47. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008; 67: 1488-1492.
48. Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010; 62: 44-52.
49. Amara K, Steen J, Murray F, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013; 210: 445-455.
50. Gomez A, Luckey D, Yeoman CJ, et al. Loss of sex and age driven differences in the gut microbiome characterize arthritis-susceptible 0401 mice but not arthritis-resistant 0402 mice. PLoS One 2012; 7: e36095.
51. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002; 168: 3649-3659.
52. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twentyyear prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902-3912.
53. Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: The role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006; 2: 679-685.
54. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-792.
55. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 1956-1963.
56. Grossman C, Dovrish Z, Shoenfeld Y, Amital H. Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev 2011; 10: 244-247.
57. Neidhart M, Kuchen S, Distler O, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 1999; 42: 389-392.
58. Lunardi C, Bason C, Navone R, et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000; 6: 1183-1186.
59. Lunardi C, Dolcino M, Peterlana D, et al. Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: A gene array approach. PLoS Med 2006; 3: e2.
60. Larsson K, Aschan J, Remberger M, Ringdén O, Winiarski J, Ljungman P. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen- identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation 2004; 77: 526-531.
61. Hamamdzic D, Harley RA, Hazen-Martin D, LeRoy EC. MCMV induces neointima in IFN-gammaR-/- mice: Intimal cell apoptosis and persistent proliferation of myofibroblasts. BMC Musculoskelet Disord 2001; 2: 3.
62. Farina A, Cirone M, York M, et al. Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol 2013; 134: 954-964.
63. Ferri C, Zakrzewska K, Longombardo G, et al. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 1999; 17: 718-720.
64. Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali- Bostwick CA, Katskikis PD. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 2011; 63: 3563-3574.
65. Rathinam VA, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010; 11: 395-402.
66. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35: 311-318.
67. Parks CG, Cooper GS, Hudson LL, et al. Association of Epstein- Barr virus with systemic lupus erythematosus: Effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum 2005; 52: 1148-1159.
68. Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther 2014; 16: R3.
69. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006; 39: 63-70.
70. Poole BD, Gross T, Maier S, Harley JB, James JA. Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun 2008; 31: 362-371.
71. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus 2009; 18: 1136-1143.
72. Li JM, Fan WS, Horsfall AC, et al. The expression of human endogenous retrovirus-3 in fetal cardiac tissue and antibodies in congenital heart block. Clin Exp Immunol 1996; 104: 388-393.
73. Somers EC, Richardson BC. Environmental exposures, epigenetic changes and the risk of lupus. Lupus 2014; 23: 568-576.
74. Zhao S, Wang Y, Liang Y, et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 2011; 63: 1376-1386.
75. Mavropoulos A, Orfanidou T, Liaskos C, et al. p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: Lessons to learn from ANCA vasculitis and pemphigus vulgaris. Autoimmun Rev 2013; 12: 580-590.
76. Mavropoulos A, Bogdanos DP, Liaskos C, et al. Flow cytometric detection of p38 MAPK phosphorylation and intracellular cytokine expression in peripheral blood subpopulations from patients with autoimmune rheumatic diseases. J Immunol Res 2014; 2014: 671431.
77. Mavropoulos A, Rigopoulou EI, Liaskos C, Bogdanos DP, Sakkas LI. The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev Immunol 2013; 2013: 569751.
78. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-17.
79. Pendergraft WF 3rd, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10: 72-79.
80. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauciimmune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088-1096.
81. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
82. Sangaletti S, Tripodo C, Chiodoni C, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 2012; 120: 3007-3018.
83. Kessenbrock K, Krumbholz M, Schönermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15: 623-625.
84. Shapira Y, Agmon-Levin N, Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 2010; 34: J168-J177.
85. Shapira Y, Agmon-Levin N, Renaudineau Y, et al. Serum markers of infections in patients with primary biliary cirrhosis: Evidence of infection burden. Exp Mol Pathol 2012; 93: 386-390.
86. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity - friends or foes? Trends Immunol 2009; 30: 409-414.
87. Berlin T, Zandman-Goddard G, Blank M, et al. Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci 2007; 1108: 584-593.
88. Agmon-Levin N, Shapira Y, Selmi C, et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun 2010; 34: 55-58.
89. Brickman CM, Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest Suppl 2001; 235: 3-15.
90. Asherson RA, Gunter K, Daya D, Shoenfeld Y. Multiple autoimmune diseases in a young woman: Tuberculosis and splenectomy as possible triggering factors? Another example of the "mosaic" of autoimmunity. J Rheumatol 2008; 35: 1224-1226.
91. Blank M, Gershwin ME. Autoimmunity: From the mosaic to the kaleidoscope. J Autoimmun 2008; 30: 1-4.
92. Shoenfeld Y, Blank M, Abu-Shakra M, et al. The mosaic of autoimmunity: Prediction, autoantibodies, and therapy in autoimmune diseases - 2008. Isr Med Assoc J 2008; 10: 13-19.
93. Bogdanos DP, Smyk DS, Invernizzi P, et al. Infectome: A platform to trace infectious triggers of autoimmunity. Autoimmun Rev 2013; 12: 726-740.
94. Bogdanos DP, Smyk DS, Invernizzi P, et al. Tracing environmental markers of autoimmunity: Introducing the infectome. Immunol Res 2013; 56: 220-240.
95. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: Current status and the future ahead. Gastroenterology 2014; 146: 1489-1499.
96. Ram M, Anaya JM, Barzilai O, et al. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev 2008; 7: 621-625.
97. Gordon J, Michel G. Discerning trends in multiplex immunoassay technology with potential for resource-limited settings. Clin Chem 2012; 58: 690-698.
98. Bissonnette L, Bergeron MG. Next revolution in the molecular theranostics of infectious diseases: Microfabricated systems for personalized medicine. Expert Rev Mol Diagn 2006; 6: 433-450.
99. Bissonnette L, Bergeron MG. Multiparametric technologies for the diagnosis of syndromic infections. Clinical Microbiology Newsletter 2012; 34: 159-168.